Theodore R. Schroeder - 31 Mar 2022 Form 4 Insider Report for Nabriva Therapeutics plc (NBRVF)

Role
Chief Executive Officer, Director
Signature
/s/ J. Christopher Naftzger, by power of attorney
Issuer symbol
NBRVF
Transactions as of
31 Mar 2022
Transactions value $
-$44
Form type
4
Date filed
04 Apr 2022, 18:27
Previous filing
08 Mar 2022
Next filing
08 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBRVF Ordinary Shares Tax liability -$44 -104 -0.03% $0.42 314K 31 Mar 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These ordinary shares were withheld by the Issuer in order to satisfy tax withholding obligations upon the vesting of certain restricted share units.